Table 3 Clinical characteristics of the patients with IgAN according to disease progression.
From: Clinical significance of urinary exosomal microRNAs in patients with IgA nephropathy
Progression (n = 21) | Non-progression (n = 34) | P | |
|---|---|---|---|
Age (years) | 51.6 ± 16.5 | 40.7 ± 15.4 | 0.020 |
Male (n, %) | 14 (66.7) | 13 (38.2) | 0.041 |
HTN (n, %) | 16 (76.2) | 12 (35.3) | 0.002 |
DM (n, %) | 1 (4.8) | 2 (5.9) | 0.859 |
BMI (kg/m2) | 25.2 ± 3.5 | 23.4 ± 2.9 | 0.052 |
Albumin (g/dL) | 3.5 ± 0.5 | 3.8 ± 0.6 | 0.156 |
IgA (mg/dL) | 309.4 ± 88.8 | 334.3 ± 109.5 | 0.905 |
eGFR (ml/min/1.73 m2) | 33.1 ± 26.0 | 79.1 ± 34.6 | < 0.0001 |
Urine PCR (g/gCr) | 3.8 ± 2.4 | 1.9 ± 2.6 | < 0.0001 |
Use of ARB or ACEi (n, %) | 18 (85.7) | 26 (76.5) | 0.394 |
Use of immunosuppressant (n, %) | 19 (90.5) | 24 (70.6) | 0.059 |
Oxford classification M (n, %) | 0.028 | ||
0 | 4 (19.0) | 16 (47.1) | |
1 | 17 (81.0) | 18 (52.9) | |
Oxford classification E (n, %) | 0.047 | ||
0 | 15 (71.4) | 32 (94.1) | |
1 | 6 (28.6) | 2 (5.9) | |
Oxford classification S (n, %) | 0.742 | ||
0 | 12 (57.1) | 21 (61.8) | |
1 | 9 (42.9) | 13 (38.2) | |
Oxford classification T (n, %) | 0.155 | ||
0 | 12 (57.1) | 26 (76.5) | |
1, 2 | 9 (42.9) | 8 (23.5) | |
Oxford classification C (n, %) | 0.070 | ||
0 | 13 (61.9) | 29 (85.3) | |
1, 2 | 8 (38.1) | 5 (14.7) |
